1. Cohn, JA, Brown, ET, Reynolds, WS, et al. Pharmacologic management of non-neurogenic functional obstruction in women. Expert Opin Drug Metab Toxicol 2016; 12: 657–667.
Google Scholar | Crossref | Medline2. Coyne, KS, Sexton, CC, Thompson, CL, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 2009; 104: 352–360.
Google Scholar | Crossref | Medline | ISI3. Irwin, DE, Milsom, I, Hunskaar, S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306–1314; discussion 1314–1315.
Google Scholar4. Nitti, VW. Pressure flow urodynamic studies: the gold standard for diagnosing bladder outlet obstruction. Rev Urol 2005; 7(Suppl. 6): S14–S21.
Google Scholar | Medline5. Higgins, JP, Green, S (eds). Cochrane handbook for systematic reviews of interventions, version 5.1.0. Chichester: The Cochrane Collaboration, 2011.
Google Scholar6. Higgins, JP, Thompson, SG, Deeks, JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.
Google Scholar | Crossref | Medline7. Guyatt, GH, Oxman, AD, Kunz, R, et al. What is ‘quality of evidence’ and why is it important to clinicians? BMJ 2008; 336: 995–998.
Google Scholar | Crossref | Medline8. Huo, LZ, Jing, HG, Wang, TC, et al. [A combination of solifenacin succinate and naftopidil in the treatment of female overactive bladder]. Zhonghua Yi Xue Za Zhi 2013; 93: 3526–3528.
Google Scholar | Medline9. Jie, H, Zheng, X, Yan, C, et al. Comparison of effect between the treatment of tolterodine combined with naftopidil and of tolterodine alone on female overactive bladder. Med J Wuhan Univ 2009; 30: 547–549.
Google Scholar10. Krhut, J, Gärtner, M, Havránek, O, et al. [Combination therapy with anticholinergics and alpha—blockers for the treatment of overactive bladder in female patients—pilot study]. Ceska Gynekol 2009; 74: 416–420.
Google Scholar | Medline11. Lee, YS, Lee, K, Lee, HS, et al. Efficacy of alpha-blocker for the treatment of voiding dysfunction in women: 8 week, randomized, double blind, placebo-controlled, parallel group study (phase E). Neurourol Urodyn 2011; 30: 1083–1084.
Google Scholar12. Lee, KS . NCT00679315: efficacy and safety of alfuzosin for the treatment of voiding dysfunction in female. NIH, https://clinicaltrials.gov/ct2/show/NCT00679315 (June 2013, accessed May 2020).
Google Scholar13. Lee, KW . NCT01533597: the efficacy of solifenacin with or without tamsulosin in adult women with overactive bladder (OAB), https://clinicaltrials.gov/ct2/show/NCT01533597 (accessed May 2020).
Google Scholar14. Lee, YS, Lee, KS, Choo, MS, et al. Efficacy of an alpha-blocker for the treatment of nonneurogenic voiding dysfunction in women: an 8-week, randomized, double-blind, placebo-controlled trial. Int Neurourol J 2018; 22: 30–40.
Google Scholar | Crossref | Medline15. Lepor, H, Theune, C. Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. J Urol 1995; 154: 116–118.
Google Scholar | Crossref | Medline | ISI16. Low, BY, Liong, ML, Yuen, KH, et al. Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial. J Urol 2008; 179: 1461–1469.
Google Scholar | Crossref | Medline | ISI17. Pummangura, N, Kochakarn, W. Efficacy of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) in women. Asian J Surg 2007; 30: 131–137.
Google Scholar | Crossref | Medline | ISI18. Robinson, D, Cardozo, L, Terpstra, G, et al. A randomized double-blind placebo controlled study to evaluated the efficacy of tamsulosin OCAS in the management of women with overactive bladder. Neurourol Urodyn 2006; 25: 620–621.
Google Scholar19. Robinson, D, Cardozo, L, Terpstra, G, et al. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int 2007; 100: 840–845.
Google Scholar | Crossref | Medline | ISI20. Yangyun, W, Xilong, W, Guowei, S, et al. Comparison of solifenacin monotherapy with solifenacin and doxazosin combination therapy for the treatment of severe overactive bladder with sexual dysfunction among youthful and middle-aged females. Chin J Androl 2014; 28: 26–31.
Google Scholar21. Yoo, C, Kim, SI, Bae, J, et al. MP75-03 a prospective randomized open-label clinical observational study to assess the effectiveness of adding tamsulosin in women treated with solifenacin for overactive bladder. J Urol 2014; 191: e874.
Google Scholar | Crossref | Medline22. Non-neurogenic female LUTS , 2021, https://uroweb.org/guideline/non-neurogenic-female-luts/
Google Scholar23. Lee, KS, Koo, KC. Clinical factors associated with the feeling of incomplete bladder emptying in women with little postvoided residue. Int Neurourol J 2020; 24: 172–179.
Google Scholar | Crossref | Medline24. Al-Zahrani, AA, Gajewski, J. Urodynamic findings in women with refractory overactive bladder symptoms. Int J Urol 2016; 23: 75–79.
Google Scholar | Crossref | Medline25. Schünemann, HJ, Cuello, C, Akl, EA, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol 2019; 111: 105–114.
Google Scholar | Crossref | Medline26. Kim, DK, Lee, JY, Jung, JH, et al. Alpha-1 adrenergic receptor blockers for the treatment of lower urinary tract symptoms in women: a systematic review and meta-analysis. Int Neurourol J 2019; 23: 56–68.
Google Scholar | Crossref | Medline